Muscle Invasive Bladder Urothelial Carcinoma
Oncology
2
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
ADC
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program1
Nadofaragene FiradenovecPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2026
2027
Ferring PharmaceuticalsNadofaragene Firadenovec
Clinical Trials (1)
Total enrollment: 33 patients across 1 trials
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
Start: Jun 2026Est. completion: Feb 202733 patients
Phase 2Not Yet Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
ADC is the dominant modality (100% of programs)
3 companies competing in this space